Liquidia Corporation

Equities

LQDA

US53635D2027

Pharmaceuticals

Real-time Estimate Cboe BZX 10:07:41 2024-04-18 am EDT 5-day change 1st Jan Change
13.78 USD -0.54% Intraday chart for Liquidia Corporation -11.25% +13.09%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Liquidia Says US FDA Cleared to Approve Yutrepia to Treat Hypertension MT
Liquidia's Yutrepia Cleared for Potential FDA Approval Following Court Ruling DJ
Liquidia Insider Sold Shares Worth $452,183, According to a Recent SEC Filing MT
Liquidia Corporation(NasdaqCM:LQDA) added to S&P Pharmaceuticals Select Industry Index CI
HC Wainwright Adjusts Price Target on Liquidia to $32 From $16, Maintains Buy Rating MT
Transcript : Liquidia Corporation, 2023 Earnings Call, Mar 13, 2024
Liquidia's 2023 Net Loss Widens, Revenue Increases -- Shares Advance Pre-Bell MT
Liquidia Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Certain Stock Units of Liquidia Corporation are subject to a Lock-Up Agreement Ending on 12-MAR-2024. CI
Certain Warrants of Liquidia Corporation are subject to a Lock-Up Agreement Ending on 12-MAR-2024. CI
Certain Options of Liquidia Corporation are subject to a Lock-Up Agreement Ending on 12-MAR-2024. CI
Certain Common Stock of Liquidia Corporation are subject to a Lock-Up Agreement Ending on 12-MAR-2024. CI
United Therapeutics Sues FDA Over Handling of Drug Application of Rival Liquidia MT
US FDA Yutrepia Review Delay 'Yet Another Setback' For Liquidia, Wedbush Says MT
Liquidia Says Yutrepia Inhalation Powder to Treat Hypertension Still Under Review by US FDA MT
Liquidia Corporation Provides Update on New Drug Application for YUTREPIA (Treprostinil) Inhalation Powder CI
Liquidia Says United Therapeutics Filed for Dismissal of Certain Claims in Patent Infringement Litigation MT
Liquidia Says Operating Chief Added to CFO Michael Kaseta's Responsibilities MT
Liquidia Corporation Announces the Launch of Yutrepiatm (Treprostinil) Inhalation Powder CI
Liquidia Corporation Announces Updates to Operations Leadership CI
Transcript : Liquidia Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 11:15 AM
Liquidia Corporation announced that it has received $74.999999 million in funding from Legend Aggregator, LP CI
Liquidia Corporation Provides Update on Clinical Pipeline Targeting PAH and PH-ILD CI
Liquidia Signs Deals for $100 Million in Additional Financings MT
Liquidia Corporation announced that it expects to receive $74.999999 million in funding from Patient Square Capital, LP CI
Chart Liquidia Corporation
More charts
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operates through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
13.86 USD
Average target price
23.86 USD
Spread / Average Target
+72.13%
Consensus
  1. Stock Market
  2. Equities
  3. LQDA Stock
  4. News Liquidia Corporation
  5. United Therapeutics Sues FDA Over Handling of Drug Application of Rival Liquidia